United Pharm Asset Resilience Ratio
United Pharm asset resilience ratio. United Pharm (033270) has an Asset Resilience Ratio of 23.98% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read United Pharm (033270) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of United Pharm (2011–2025)
Asset resilience ratio of United Pharm from 2011 to 2025. This chart shows how United Pharm's Asset Resilience Ratio has changed over time. See cash generation quality of United Pharm to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down United Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 033270 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩136.89 Billion | 23.98% |
| Total Liquid Assets | ₩136.89 Billion | 23.98% |
Asset Resilience Insights
- Good Liquidity Position: United Pharm maintains a healthy 23.98% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
United Pharm Industry Peers by Asset Resilience Ratio
Compare United Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Abbott India Limited
NSE:ABBOTINDIA |
Drug Manufacturers - Specialty & Generic | 53.22% |
|
Shenzhen Salubris Pharmaceuticals Co Ltd
SHE:002294 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
United Pharm Asset Resilience Ratio by Year (2011–2025)
United Pharm asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for United Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.48% | ₩116.77 Billion ≈ $79.13 Million |
₩519.49 Billion ≈ $352.05 Million |
+1.67pp |
| 2024-12-31 | 20.81% | ₩98.61 Billion ≈ $66.83 Million |
₩473.93 Billion ≈ $321.17 Million |
-6.31pp |
| 2023-12-31 | 27.12% | ₩127.14 Billion ≈ $86.16 Million |
₩468.86 Billion ≈ $317.74 Million |
-0.58pp |
| 2022-12-31 | 27.70% | ₩115.74 Billion ≈ $78.43 Million |
₩417.89 Billion ≈ $283.20 Million |
+11.28pp |
| 2021-12-31 | 16.41% | ₩62.37 Billion ≈ $42.27 Million |
₩380.03 Billion ≈ $257.54 Million |
+1.20pp |
| 2020-12-31 | 15.21% | ₩53.76 Billion ≈ $36.44 Million |
₩353.43 Billion ≈ $239.52 Million |
+3.71pp |
| 2019-12-31 | 11.50% | ₩38.09 Billion ≈ $25.81 Million |
₩331.24 Billion ≈ $224.48 Million |
-0.82pp |
| 2018-12-31 | 12.32% | ₩37.19 Billion ≈ $25.20 Million |
₩301.95 Billion ≈ $204.63 Million |
+0.09pp |
| 2017-12-31 | 12.23% | ₩32.51 Billion ≈ $22.03 Million |
₩265.80 Billion ≈ $180.13 Million |
+1.69pp |
| 2016-12-31 | 10.54% | ₩24.70 Billion ≈ $16.74 Million |
₩234.22 Billion ≈ $158.73 Million |
+5.15pp |
| 2014-12-31 | 5.40% | ₩11.72 Billion ≈ $7.94 Million |
₩217.10 Billion ≈ $147.13 Million |
+5.08pp |
| 2013-12-31 | 0.32% | ₩615.09 Million ≈ $416.84K |
₩193.54 Billion ≈ $131.16 Million |
-4.67pp |
| 2012-12-31 | 4.99% | ₩9.36 Billion ≈ $6.34 Million |
₩187.58 Billion ≈ $127.12 Million |
+4.76pp |
| 2011-12-31 | 0.23% | ₩384.56 Million ≈ $260.61K |
₩170.09 Billion ≈ $115.26 Million |
-- |
About United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to app… Read more